6 employees
Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide.
2005
Proterris, Inc raised undisclosed on December 31, 2017
Investors: Portugal Ventures